Opendata, web and dolomites

OXIFLOW SIGNED

Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIFLOW project word cloud

Explore the words cloud of the OXIFLOW project. It provides you a very rough idea of what is the project "OXIFLOW" about.

transfer    whom    fd    avoidable    generating    principles    device    performance    51    unruptured    apposition    treatment    business    suffer    02m    manufacture    addressable    intracranial    cumulative    first    ia    disabilities    diverters    central    resolution    ias    56m    natural    tortuous    poor    ing    entirely    causes    radial    vessels    innovative    excellent    40    away    pilot    period    inherent    fim    citizens    invasive    delivering    die    flow    minimally    aneurysm    man    mesh    small    shape    options    risk    73    coiling    subarachnoid    revenues    utilises    overcoming    sah    severe    memory    oxiflow    restrict    surgical    oe    clipping    patient    risky    limitations    optimum    complete    coning    guidewire    forces    reporting    rupture    each    origami    failed    expectations    fds    healing    463m    cheaper    blood    weak    lower    ethical    thereby    porosity    endovascular    live    nitinol    regulatory    inferior    extension    safety    material    expensive    procedure    made    poorer    freeze    approvals    market    vessel    divert    whilst    uniform    haemorrhage    clinical   

Project "OXIFLOW" data sheet

The following table provides information about the project.

Coordinator
OXFORD ENDOVASCULAR LIMITED 

Organization address
address: 9400, GARSINGTON ROAD, OXFORD
city: OXFORD
postcode: OX4 2HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 4˙232˙828 €
 EC max contribution 2˙962˙979 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXFORD ENDOVASCULAR LIMITED UK (OXFORD) coordinator 2˙962˙979.00

Map

 Project objective

Each year ~51,000 EU citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH’s are entirely avoidable through treatment of ‘at risk’ unruptured IAs.

Existing treatment options include: surgical clipping, an invasive, risky and expensive procedure but delivering excellent long-term resolution; and endovascular coiling, a cheaper and lower risk minimally invasive procedure but delivering poorer long-term resolution. Flow diverters (FDs) are an emerging endovascular device that divert blood flow away from the aneurysm thereby enabling natural healing. Whilst offering the potential of excellent long-term resolution at low risk and cost, existing FDs have failed to live up to expectations, reporting performance inferior to coiling. Limitations of existing FD’s are inherent to their mesh design that causes weak and non-uniform radial forces resulting in poor vessel apposition, variable porosity and device coning. Existing delivery systems also restrict use due to extension of the central guidewire during delivery.

OxiFlow is a unique FD design based on origami principles and made from a shape memory Nitinol material. The innovative design enables optimum and uniform radial forces thereby overcoming the limitations of existing FDs. Furthermore, OxiFlow utilises a novel delivery system enabling complete user control of the central guidewire extension and thus use in small and tortuous vessels.

OXIFLOW will evaluate safety and performance of the OxiFlow device through a 10-patient First-in-Man (FIM) study. Project activities include: device design freeze, transfer to pilot scale manufacture, pre-clinical testing; regulatory and ethical approvals; and FIM study implementation.

The addressable EU & US market for OxiFlow is estimated at €463M. OE target €40.02M business growth over a 5-year period generating €73.56M cumulative revenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIFLOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIFLOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More